Document Detail

Serum sialic acid changes in type 2 diabetic patients on metformin or rosiglitazone treatment.
MedLine Citation:
PMID:  21054460     Owner:  NLM     Status:  MEDLINE    
WHAT IS KNOWN AND OBJECTIVE: Serum sialic acid is a recently investigated potential risk-marker for cardiovascular complications. There is a known association between sialic acid and cardiovascular complications in diabetes mellitus. We aimed to investigate the effect of antidiabetic drugs on the serum concentration of sialic acid.
METHODS: We investigated the effect of metformin and rosiglitazone on the concentration of sialic acid in 120 type 2 diabetic patients, divided into a group (n = 60) receiving metformin and a group (n = 60) receiving rosiglitazone treatment.
RESULTS: Serum sialic acid was significantly higher in patients on rosiglitazone (66·90 ± 8·80 mg/dL vs. 57·6 ± 8·46 mg/dL, P < 0·01) and metformin (61·95 ± 10·49 mg/dL vs. 57·6 ± 8·46 mg/dL, P < 0·04) when compared with control subjects. In addition, rosiglitazone-treated patients showed a significant increase in cardiovascular risk factors, notably total cholesterol (246·45 ± 20·2 mg/dL vs. 170·6 ± 15·1 mg/dL, P = 0·01), triglyceride (178 ± 9·20 mg/dL vs. 149·35 ± 6·31 mg/dL, P < 0·04) and glycohemoglobin (HbA1-c) concentration (8·17 ± 1·43% vs. 4·38 ± 0·96%, P < 0·02) compared with normal control subjects. The patients on metformin also showed significantly higher levels of serum glucose (133·7 ± 9·63 mg/dL vs. 88·35 ± 6·31 mg/dL, P < 0·04) and glycohemoglobin (HbA1-c) (8·23 ± 1·75% vs. 4·38 ± 0·96%, P < 0·02) when compared with control subjects. Comparison of the two groups of patients revealed a significantly higher serum sialic acid (66·90 ± 8·80 mg/dL vs. 61·95 ± 10·49 mg/dL, P < 0·05), total cholesterol (246·45 ± 20·2 mg/dL vs. 192 ± 14·23 mg/dL, P < 0·02) and triglyceride (178 ± 9·20 mg/dL vs. 158 ± 14·51mg/dL, P < 0·05) concentrations in the rosiglitazone-treated patients.
WHAT IS NEW AND CONCLUSIONS: This study suggests significantly higher levels of serum sialic acid and other cardiovascular risk factors in rosiglitazone-treated patients than in metformin-treated patients. The lower sialic acid concentration may explain a better metformin antidiabetic effect than with rosiglitazone.
I U Rahman; S A Malik; M Bashir; R U Khan; M Idrees
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical pharmacy and therapeutics     Volume:  35     ISSN:  1365-2710     ISO Abbreviation:  J Clin Pharm Ther     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-08     Completed Date:  2011-05-17     Revised Date:  2012-09-10    
Medline Journal Info:
Nlm Unique ID:  8704308     Medline TA:  J Clin Pharm Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  685-90     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Faculty of Biological Sciences, Quaid e Azam University, Islamabad, Pakistan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood
Blood Glucose / drug effects
Cardiovascular Diseases / etiology
Cholesterol / blood
Diabetes Mellitus, Type 2 / blood,  drug therapy*
Hemoglobin A, Glycosylated / metabolism
Hypoglycemic Agents / therapeutic use*
Lipids / blood
Metformin / therapeutic use*
N-Acetylneuraminic Acid / blood*
Risk Factors
Thiazolidinediones / therapeutic use*
Triglycerides / blood
Reg. No./Substance:
0/Biological Markers; 0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Lipids; 0/Thiazolidinediones; 0/Triglycerides; 122320-73-4/rosiglitazone; 131-48-6/N-Acetylneuraminic Acid; 57-88-5/Cholesterol; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Methylprednisolone reduces postoperative nausea in total knee and hip arthroplasty.
Next Document:  Modification of propranolol's bioavailability by Eurycoma longifolia water-based extract.